Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/annonc/mdp566 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS).
Front Pharmacol
January 2024
Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
This study attempted to identify similarities and differences in adverse events (AEs) between human epidermal growth factor receptor 2 (HER2) inhibitors, especially those related to hemorrhagic events and nervous system disorders. This study summarized the types, frequencies, and system organ classes (SOCs) of AEs of HER2 inhibitors. The US Food and Drug Administration Adverse Event Reporting System (FAERS) data from January 2004 through March 2022 was collected and analyzed.
View Article and Find Full Text PDFSevere thrombocytopenia related to trastuzumab infusion.
Med Sci Monit
July 2011
1st Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Laiko General Hospital, Athens, Greece.
Background: Trastuzumab is a humanized, monoclonal antibody that interferes with the HER2/neu receptor and binds selectively to the HERB2 protein which causes uncontrolled proliferation of malignant breast cells.
Case Report: We report a case of severe thrombocytopenia related to trastuzumab administration. Three days after the first dose of single-agent trastuzumab, the patient was admitted to the hospital with nose bleeding, petechiae and platelet counts of 5 × 10⁹/L.
Trastuzumab-related thrombocytopenia: always a self-limiting complication?
Ann Oncol
March 2010
Department of Oncology and Oncohematology, Infermi Hospital, Rimini; Cancer Institute of Romagna, Meldola, Italy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!